nach oben

Familial Cancer

Erschienen in:

26.02.2016 | Original Article

Evolution of cancer risk assessment and counseling related to psychological, financial and legal implications

verfasst von: Carrie Snyder

Erschienen in: Familial Cancer | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Cancer risk assessment, genetic counseling and genetic testing have experienced advances and changes over the past two decades due to improved technology, legal movements to protect those at an increased risk for cancer due to genetics, as well as advances in detection, prevention and treatment. This brief article will provide a summary of these advances over three eras of cancer genetics: pre-discovery of the more common high impact genes, namely BRCA1/BRCA2 and the mismatch repair genes associated with Lynch syndrome; the time during which the genes were being discovered; and current day.

Lynch HT, Snyder C, Lynch JF, Karatoprakli P, Trowonou A, Metcalfe K, Narod SA, Gong G (2006) Patient responses to the disclosure of BRCA mutation tests in hereditary breast–ovarian cancer families. Cancer Genet Cytogenet 165:91–97CrossRefPubMed

Lerman C, Hughes C, Lemon SJ, Main D, Snyder C, Durham C, Narod S, Lynch HT (1998) What you don’t know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol 16:1650–1654PubMed

Wagner TMU TMU, Möslinger R, Langbauer G G, Ahner R, the Austrian Hereditary Breast and Ovarian Cancer Group, Fleischmann E, Auterith A, Friedmann A, Helbich T, Zielinski C, Pittermann E, Seifert M, Oefner P (2000) Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Br J Cancer 82:1249–1253CrossRef

Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA (2011) Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 155:69–79CrossRefPubMedPubMedCentral

Kuehn BM (2013) Supreme Court rules against gene patents. JAMA 310:357–359CrossRefPubMed

Katskee v (1994) Blue Cross/Blue Shield of Nebraska, Nebraska Supreme Court No. S-92-1002

National Comprehensive Cancer Network (2015) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) Genetic/familial high-risk assessment: breast and ovarian. Version 2.2015. http://www.NCCN.org. Accessed 15 Feb 2016

National Comprehensive Cancer Network (2015) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) Genetic/familial high-risk assessment: colorectal, Version 2.2015. http://www.NCCN.org. Accessed 15 Feb 2016

Burn J, Gerdes A-M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, Eccles D, Evans G, Maher ER, Bertario L, Bisgaard M-L, Dunlop MG, Ho JWC, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJW, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop T, on behalf of the CAPP2 investigators (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081–2087CrossRefPubMedPubMedCentral

10.

Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG (2007) Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 25:3985–3990CrossRefPubMed

11.

Casey MJ, Colanta A (2016) Mullerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery (in press). Fam Cancer [Note: This will be published in the same issue.]

12.

Natarajan N, Watson P, Silva-Lopez E, Lynch HT (2010) Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum 53:77–82CrossRefPubMed

13.

Livraghi L, Garber JE (2015) PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 13:188CrossRefPubMedPubMedCentral

14.

Koido S, Ohkusa T, Homma S, Namiki Y, Takakura K, Saito K, Ito Z, Kobayashi H, Kajihara M, Uchiyama K, Arihiro S, Arakawa H, Okamoto M, Gong J, Tajiri H (2013) Immunotherapy for colorectal cancer. World J Gastroenterol 19:8531–8542CrossRefPubMedPubMedCentral

15.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520CrossRefPubMed

16.

Ott PA, Hodi S, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300–5309CrossRefPubMed

17.

Zhu L, Jing S, Wang B, Wu K, Shenglin MA, Zhang S (2015) Anti-PD-1/PD-L1 therapy as a promising option for non-small cell lung cancer: a single arm meta-analysis. Pathol Oncol Res. doi:10.1007/s12253-015-0011-z

18.

Hudson KL, Holohan MK, Collins FS (2008) Keeping pace with the times—the Genetic Information Nondiscrimination Act of 2008. N Engl J Med 358:2661–2663CrossRefPubMed

Titel: Evolution of cancer risk assessment and counseling related to psychological, financial and legal implications
verfasst von: Carrie Snyder
Publikationsdatum: 26.02.2016
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 3/2016
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-016-9890-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Evolution of cancer risk assessment and counseling related to psychological, financial and legal implications

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Recent discoveries in the molecular genetics of Lynch syndrome

Colonoscopy and chromoscopy in hereditary colorectal cancer syndromes

Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target

Chemoprevention of familial adenomatous polyposis

Genetic counseling and cascade genetic testing in Lynch syndrome

Introduction to special issue of Familial Cancer

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie